Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic

Nicole DeFeudis

Editor

A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Haney is reeling in another $133 million for Skyhawk Therapeutics. And it sounds like he’s got the S-1 papers in his back pocket.

Skyhawk unveiled the latest round led by Fidelity Management and Research on Tuesday morning, which Haney says is likely the company’s last venture round before going public. Other big name investors like GreatPoint Ventures and Rock Springs Capital also chipped in.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

Asset Management Administrator

Lonza

Houston, TX, USA

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Novartis unveils new brand identity after Sandoz spinoff

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Bill Haney adds an­oth­er $133M to Sky­hawk's cof­fers, as the RNA start­up guns for the clin­ic

Editor

Unlock this article instantly by becoming a free subscriber.

Lonza

Houston, TX, USA

Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic